Skip to main content
. 2017 Nov 24;8(65):109151–109160. doi: 10.18632/oncotarget.22642

Figure 2. CD122 mAb treatment suppressed CT26 and B16-OVA tumor growth and enhanced long-term survival.

Figure 2

Treatment regimen, individual tumor growth, group tumor measurements, and survival of CT26 (A) and B16-OVA (B) implanted mice following treatment are indicated. Figures represent 2 (CT26) and 3 (B16-OVA) independent experiments. **P<0.01; ***P<0.001; ****P<0.0001.